Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $107.90 Average Target Price from Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $106.50.

GPCR has been the subject of several recent analyst reports. Stifel Nicolaus upped their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday. Finally, Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently added to or reduced their stakes in GPCR. Morgan Stanley grew its stake in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter valued at $61,086,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Key Stories Impacting Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: Positive Phase 2 ACCESS II topline data: ACCESS II showed placebo‑adjusted mean weight loss of 16.3% (~39 lbs) at 180 mg and 16.0% (~37 lbs) at 240 mg at 44 weeks, with no evidence of an early plateau — results the company says rank among the highest for oral GLP‑1s and are comparable to injectables. Press Release
• Positive Sentiment: Heavy media coverage highlights outsized efficacy vs. oral peers and potential market opportunity (reports cite up to ~16% weight loss / 39 lbs), driving investor excitement and secondary trading interest. Representative coverage: Investors Business Daily and Benzinga. Investors Article Benzinga Article
• Neutral Sentiment: Analyst update: HC Wainwright trimmed its price target from $114 to $100 but kept a “Buy” rating — still implies substantial upside from current levels, so the note is overall constructive despite the PT cut. Benzinga
• Negative Sentiment: Earlier financial performance: the company reported an EPS miss in its Feb 26 quarter (a negative reminder that GPCR remains pre‑commercial and will need further data, regulatory clarity, and capital to reach commercialization), which could temper longer‑term valuation until confirmatory trials and development milestones are delivered.

Structure Therapeutics Price Performance

Shares of GPCR opened at $56.65 on Tuesday. Structure Therapeutics has a one year low of $13.22 and a one year high of $94.90. The company has a market cap of $4.01 billion, a P/E ratio of -71.71 and a beta of -1.79. The firm has a 50 day simple moving average of $73.33 and a two-hundred day simple moving average of $49.98.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). On average, analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.